公开(公告)号：US20240299380A1

公开(公告)日：2024-09-12

申请号：US18572432

申请日：2022-06-21

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： Jing Guo ,  Dan Yan ,  Yu Wang ,  Tong Xu ,  Kao Li ,  Wei Xu ,  Hong Lan ,  Lieming Ding ,  Jiabing Wang

IPC: A61K31/4985 ,  A61P35/00

CPC classification number: A61K31/4985 ,  A61P35/00

Abstract: The present invention provides an application of a compound in the preparation of drug for treating myelofibrosis and the related symptoms/signs thereof, and a use of the compound. The compound is selected form one or more of a compound having a structure as shown in formula I, and a pharmaceutically-acceptable salt, prodrug, solvate and hydrate thereof.

公开(公告)号：US11466013B2

公开(公告)日：2022-10-11

申请号：US16973335

申请日：2019-06-06

Applicant: Betta Pharmaceuticals Co., LTD

Inventor： Hao Wu ,  Wei Gu ,  Xiaojing Tang ,  Wei Wang ,  Bo Zhan ,  Dongjie Feng ,  Yongxin Ke ,  Zhongyan Chen ,  Yifei Shen ,  Wenmao Wu ,  Xintao Zhao ,  Hong Lan ,  Jiabing Wang ,  Lieming Ding

IPC: C07D487/04 ,  A61P35/00 ,  C07D401/04 ,  C07D403/14 ,  C07D417/04 ,  C07D487/20 ,  C07D491/20 ,  C07D513/04 ,  C07D519/00

Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.

公开(公告)号：US20220259235A1

公开(公告)日：2022-08-18

申请号：US17629976

申请日：2020-07-23

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Xiangyong Liu ,  Changyong Qiu ,  Qichao Shen ,  Mengqiang Liu ,  Haitong Sheng ,  Xiaodong Song ,  Guolong Du ,  Jiabing Wang ,  Lieming Ding

IPC: C07F9/6558 ,  A61P35/00 ,  C07F9/6561

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US11053238B2

公开(公告)日：2021-07-06

申请号：US16471415

申请日：2017-12-22

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Yiqian Wang ,  Jiabing Wang ,  Lieming Ding

IPC: C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  A61P35/04

Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

公开(公告)号：US12043622B2

公开(公告)日：2024-07-23

申请号：US17254097

申请日：2019-06-21

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Yiqian Wang ,  Chunhui Zhang ,  Jiabing Wang ,  Lieming Ding

IPC: C07D471/04 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07B2200/13

Abstract: The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

公开(公告)号：US11845762B2

公开(公告)日：2023-12-19

申请号：US17898258

申请日：2022-08-29

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Yan Xu ,  Xiaofeng Xu ,  Jiabing Wang ,  Lieming Ding

IPC: C07D519/00 ,  C07D471/06

CPC classification number: C07D519/00 ,  C07D471/06 ,  C07B2200/13

Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

公开(公告)号：US20210130345A1

公开(公告)日：2021-05-06

申请号：US16471415

申请日：2017-12-22

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Yiqian Wang ,  Jiabing Wang ,  Lieming Ding

IPC: C07D471/04 ,  A61P35/04 ,  C07D498/04 ,  C07D487/04

Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

公开(公告)号：US20160108055A1

公开(公告)日：2016-04-21

申请号：US14896992

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Shaojing Hu ,  Wei Long ,  Fei Wang ,  Yinxiang Wang ,  Lieming Ding

IPC: C07D491/056 ,  A61K9/48 ,  A61K9/20 ,  A61K31/519 ,  A61K45/06

CPC classification number: C07D491/056 ,  A61K9/20 ,  A61K9/48 ,  A61K31/519 ,  A61K45/06

Abstract: The present invention relates to the polymorphic forms of the compound of Formula I, preparation thereof and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition.

Abstract translation: 本发明涉及式I化合物的多晶形式，其制备方法和药物组合物，以及上述多晶型物在疾病，病症或病症的治疗中的用途，或用于制备用于治疗的药物 疾病，疾病或病症。

公开(公告)号：US20250051301A1

公开(公告)日：2025-02-13

申请号：US18847130

申请日：2023-03-14

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： Yabin Li ,  Xiaofeng Xu ,  Xizhen Song ,  Jingwei Ding ,  Yunlai Zhang ,  Jie Chen ,  Xiangyong Liu ,  Lieming Ding ,  Jiabing Wang

IPC: C07D401/04 ,  A61K31/53

Abstract: Disclosed are a compound represented by formula (I) as a mutant isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) inhibitor, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed is a use of the described compound or the pharmaceutical composition thereof in the treatment of mutant IDH1 and IDH2-mediated diseases.

公开(公告)号：US11466034B2

公开(公告)日：2022-10-11

申请号：US16954901

申请日：2018-12-20

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Yan Xu ,  Xiaofeng Xu ,  Jiabing Wang ,  Lieming Ding

IPC: C07D519/00 ,  C07D471/06

Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.